ACTA1 and Hepatic fibrosis: showed that the intraperitoneal injection of TAA (100 mg/kg) for 2 weeks resulted in a substantial increment in hepatic fibrosis markers as TGF‐β1, collagen I, connective tissue growth factor (CTGF), focal adhesion kinase (FAK) and α‐SMA.